SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 32.93+2.9%Nov 18 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cacaito who wrote (13688)5/28/2000 10:58:00 AM
From: Bluegreen  Read Replies (2) of 17367
 
Cacaito, what is this worth if approved??????>>>>>>>>XOMA Initiates Phase I/II Clinical Study of Anti-CD11a in Kidney Transplant Patients
BERKELEY, Calif.--(BW HealthWire)--March 30, 2000--XOMA Ltd. (Nasdaq:XOMA) today announced the initiation of a Phase I/II clinical study of anti-CD11a in kidney transplant recipients.
XOMA is collaborating with Genentech, Inc. (NYSE:DNA) to develop this recombinant, humanized monoclonal antibody designed to selectively inhibit immune system T cells. This is the second indication being evaluated for this investigational antibody; a Phase III trial of anti-CD11a in patients with moderate-to-severe plaque psoriasis began in December 1999.
"T cells are involved in the immune system's rejection of transplanted organs as well as in autoimmune diseases like psoriasis," said Marvin Garovoy, MD, Vice President of Clinical and Medical Affairs at XOMA. "We believe that anti-CD11a may have potential advantages over immunosuppressive drugs currently used to prevent organ transplant rejection. Initially, we will study the antibody in combination with standard immunosuppressive drugs to test its safety in this population and to see if it further reduces graft rejection. Ultimately, anti-CD11a may allow reduced use of other agents, potentially making for a safer and more effective therapeutic regimen."<<<<<<<<<<<
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News